Advancing Hope: AFTD Attends 2024 Society for Neuroscience Meeting
Dr. Nicole Bjorklund, AFTD Director of Research and Grants, and Dr. Kate Still, Research Outreach Manager, attended the Society for Neuroscience meeting in October to take in the latest research…
Read MoreNew York Software Company Awards AFTD Gift to Honor Employee’s Late Cousin
AFTD has been selected as one of three organizations to receive a gift from Mindex, a software-development company in Rochester, N.Y., in honor of the latter’s 30th anniversary charity initiative.…
Read MoreTransposon Presents Results from Successful Phase 2 ALS/FTD Clinical Trial
Biotechnology company Transposon Therapeutics presented the results from its successful phase 2 clinical trial of its experimental medication for ALS/FTD at the 35th International Symposium on ALS/MND. The trial of…
Read MoreAviadoBio CEO Emphasizes Collaborative Approach for Treating FTD
In October, U.K.-based gene therapy company AviadoBio, Ltd., and pharmaceutical company Astellas announced an exclusive option and license agreement for an investigational therapeutic, AVB-101, which is currently in a Phase…
Read MoreJanuary 11, 2025: In-Person Meet & Greet in Middlesex, N.J.
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD volunteer Norma Edom and AFTD Ambassador Sandra Gonzalez-Morett at…
Read MoreIn-Person Meet & Greet in Middlesex, N.J.
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD volunteer Norma Edom and AFTD Ambassador Sandra Gonzalez-Morett. RSVP…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)